Kirov Plazma

2017: Nacimbio, Pharmstandard and Kedrion Biopharma create JV Kirov Plazma

"The national immunobiological company" (enters into State Corporation Rostec), Pharmstandard and Kedrion Biopharma (Italy) signed the agreement on creation of Kirov Plasma joint-stock company in March, 2017. The enterprise will develop and implements the program of production in the Russian Federation of the medicines received from plasma of blood of the person based on Kirov Plant. Kedrion Biopharma share in authorized capital makes 25%, Nacimbio and Pharmstandard – on 37.5% at each company.

Подписание проходило в здании Ростеха в присутствии генерального директора Госкорпорации Sergey Chemezov and acting as governor of the Kirov region Igor Vasilyev.

"Kirov Plasma" will provide complete hardware of the enterprise and validates production of the medicines received from plasma of blood of the person. It is planned that the basic project will be prepared in the third quarter 2017.

"We are faced by a task of liquidation of dependence of Russia on import biological and medicines. Today 100% of factors of coagulability of blood 8 and 9, vital the patient with hemophilia, are bought abroad. In general in a segment of medicines of blood up to 90% is import. After reaching of the plant production capacity the Russian health care will be completely provided with albumine, immunoglobulin and factors of folding 8 and 9", – the CEO of Nacimbio Maryam Hubiyeva noted.

Kedrion Biopharma enters in top-5 the largest world processors of plasma of blood and openly declares interest in development in the Russian market. Within cooperation Kedrion will act as the technology partner, will transfer registration certificates, will perform a transfer of a line of medicines, will provide the platform with necessary production technologies, managements, control procedures, will organize a training of employees "Kirov Plasma" at the plants of the company.

"The joint venture with two leading Russian pharmaceutical companies is an important milestone in the history of Kedrion. We are very glad to an opportunity to act as the key technology partner in the project, so significant for Russia", – Maria Lina Markuchchi, the board member of Kedrion Biopharma said.

"Kirov Plant had to earn in 2009, but because of unresolved financial and organizational issues of a project work were frozen. It is sure that, having combined efforts, competences and resources of Pharmstandard, Rostec and the Italian partners, the Kirov project representing huge importance for a health care system of the Russian Federation will be started", – the CEO of PJSC Pharmstandard Grigory Potapov told.

"Start of the plant on production of medicines of blood in Kirov has a strategic importance not only for the region, but also for the country in general. We see a difficult international situation, need of import substitution for a number of the industries. The domestic health care annually needs the considerable amount of medicines of blood for treatment of more than 1 million patients. For today this requirement is satisfied generally for the purchases account of expensive medicines of foreign production. The Kirov Plasma company which will be engaged in completion and start of a property complex created the program of development of the plant with clear perspective: it will be constructed on the most modern technologies on new technology conditions, and the products will allow to provide import substitution in the most costly to the pharmaceutical industry for today", – the Acting the governor of the Kirov region Igor Vasilyev said.

2016: Nacimbio and Kedrion Biopharma sign the memorandum of cooperation

In December, 2016 Nacimbio signed the memorandum of cooperation according to which Kedrion Biopharma will transfer the production technology of medicines and will implement a quality control system, and Pharmstandard will act as the co-investor.

In December, 2016 the parties signed the memorandum of joint project implementation in the field of production of medicines of plasma of blood assuming creation of joint venture for localization of production for a full stroke of medicines for treatment of socially important diseases.